soul trial oral semaglutide cardiovascular outcomes results 2024 nejm (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine Oral Semaglutide and Cardiovascular Outcomes

With everything handled through a single complete service, you avoid the complexity of coordinating between multiple providers

No retention attempts, no guilt trips, no runaround

In addition, it has a wide variety of advantages for disorders associated with cognitive deficiencies of the brain, which reveals improvements in attention, memory, sociability and focus while reducing ASD symptom severity, and it does not have any negative effects on the body

Its sometimes added to GLP-1 therapies to help reduce fatigue

This deficiency can occur as a primary one due to genetic disorder that disrupts carnitine transport, or as a secondary one coming from problems such as malnutrition, certain medical conditions, or the intake of particular medications

The role of the vagus nerve in appetite control: implications for the pathogenesis of obesity